サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791538

バイオマーカー検査サービスの世界市場

Biomarker Testing Services

出版日
ページ情報
英文 152 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
バイオマーカー検査サービスの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 152 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

バイオマーカー検査サービスの世界市場は2030年までに11億米ドルに達する見込み

2024年に7億50万米ドルと推定されたバイオマーカー検査サービスの世界市場は、2030年には11億米ドルに達し、分析期間2024-2030年のCAGRは8.1%で成長すると予測されます。本レポートで分析したセグメントの1つであるバイオマーカーアッセイ開発・検証サービスは、CAGR 8.3%を記録し、分析期間終了時には7億6,260万米ドルに達すると予測されます。フローサイトメトリーサービスセグメントの成長率は、分析期間中CAGR 7.4%と推定されます。

米国市場は1億8,410万米ドルと推定、中国はCAGR7.9％で成長予測

米国のバイオマーカー検査サービス市場は、2024年に1億8,410万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億7,870万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.5％と6.8％と予測されています。欧州では、ドイツがCAGR約6.5％で成長すると予測されています。

世界のバイオマーカー検査サービス市場- 主要動向と促進要因のまとめ

なぜバイオマーカー検査は現代ヘルスケアで重要性を増しているのか？

バイオマーカー検査は、疾患の早期発見、治療モニタリング、標的治療のための患者層別化を可能にする精密医療の要となっています。がん、心血管疾患、自己免疫疾患などの慢性疾患の有病率の上昇に伴い、信頼性の高いバイオマーカー検査サービスに対するニーズが急増しています。これらのサービスは、より正確な診断と治療法の選択を容易にし、患者の転帰の改善とヘルスケアコストの削減を保証します。バイオマーカーに基づく診断への依存の高まりは、個別化医療の急速な拡大にも表れています。製薬会社は、バイオマーカー検査を医薬品開発プロセスに組み込み、特定の治療法が最も有効な患者集団を特定しています。さらに、規制当局はコンパニオン診断薬にバイオマーカー検査を義務付け、市場承認前に薬剤の有効性と安全性を確認するようになっています。その結果、ヘルスケアプロバイダーや診断ラボは、高度な分析能力を持つ専門ラボにバイオマーカー検査サービスをアウトソーシングする傾向が強まっています。

技術革新はどのようにバイオマーカー検査サービスを強化しているか？

ゲノミクス、プロテオミクス、バイオインフォマティクスの技術的進歩は、バイオマーカー検査サービスに革命をもたらし、より正確で、費用対効果が高く、利用しやすくなっています。次世代シークエンシング（NGS）とポリメラーゼ連鎖反応（PCR）技術により、遺伝子バイオマーカーや分子バイオマーカーの検出が向上し、より早期の疾患同定やリスク評価が可能になりました。さらに、バイオマーカーデータ解析における人工知能（AI）と機械学習の統合は、検査の精度を最適化し、結果の解釈を加速しています。リキッドバイオプシー技術の出現は、バイオマーカー検査におけるもう一つの画期的な開発です。これらの低侵襲検査は、血液サンプル中の循環腫瘍DNA（ctDNA）やその他のバイオマーカーを分析することにより、疾患の進行をリアルタイムでモニタリングすることを可能にします。さらに、マルチプレックスバイオマーカーアッセイの進歩により、複数のバイオマーカーを同時に検査することが可能になり、従来の単一マーカー検査に関連する時間とコストを削減することができます。ヘルスケアがデータ主導の意思決定に移行する中、こうした技術革新により、バイオマーカー検査サービスは最新の診断学や医薬品開発において不可欠なツールとなっています。

バイオマーカー検査サービスの成長を促進する市場動向とは？

バイオマーカー検査サービス市場を推進している主な動向の一つは、病気の早期発見と個別化治療計画に対する需要の高まりです。ヘルスケアプロバイダーや研究者は、個々の患者プロファイルに合わせた治療を行うために精密診断を優先しており、様々な医療専門分野でのバイオマーカー検査の採用が増加しています。腫瘍学は依然として最大の応用分野であり、免疫療法、標的がん治療、化学療法反応性評価においてバイオマーカー主導型治療が重要な役割を果たしています。市場を形成するもう一つの重要な動向は、分散型検査モデルの台頭です。遠隔医療および遠隔患者モニタリング技術の進歩により、在宅およびポイントオブケア型のバイオマーカー検査へのシフトが加速しています。各社はポータブルバイオマーカー検査キットやウェアラブルバイオセンサーを開発し、リアルタイムの健康追跡を容易にすることで、頻繁な通院の必要性を減らしています。さらに、バイオマーカー主導の臨床試験や医薬品承認に対する規制当局の支援が、バイオマーカー検査を開発パイプラインに組み込むことを製薬企業に促しており、市場の需要をさらに押し上げています。

バイオマーカー検査サービス市場の主な成長促進要因は？

バイオマーカー検査サービス市場の成長は、慢性疾患の罹患率の上昇、プレシジョン・メディシンの採用の増加、バイオマーカー検出法の急速な技術進歩など、いくつかの要因によってもたらされます。薬剤の承認や患者の選択にバイオマーカー検査を必要とするコンパニオン診断の拡大は、市場の成長をさらに促進しています。さらに、臨床研究とバイオテクノロジーの革新への投資の増加は、バイオマーカー検査の応用範囲を拡大しています。製薬企業は、医薬品開発の合理化、臨床試験の失敗の削減、規制遵守の強化のためにバイオマーカー検査サービスを活用しています。リキッドバイオプシーやマルチプレックスバイオマーカーパネルのような非侵襲的診断技術へのシフトも市場拡大を加速しています。世界中のヘルスケアシステムが診断精度と治療効果の向上に注力する中、バイオマーカー検査サービスは持続的な成長を遂げ、疾病管理と精密医療の未来を変えると予想されます。

セグメント

サービス（バイオマーカーアッセイ開発・検証サービス、フローサイトメトリーサービス、その他サービス）、タイプ（分子バイオマーカー、細胞バイオマーカー）、エンドユーザー（製薬・バイオテクノロジー企業エンドユーザー、研究機関エンドユーザー、CROエンドユーザー）

調査対象企業の例

  • ACM Global Laboratories
  • BioAgilytix Labs, LLC
  • Biomedica Medizinprodukte GmbH
  • Charles River Laboratories, Inc.
  • Creative Biolabs
  • Discovery Life Sciences
  • Frontage Laboratories, Inc.
  • Intertek Group Plc
  • Laboratory Corporation of America Holdings
  • NorthEast BioLab
  • Novigenix SA
  • Pacific Biolabs
  • Randox Laboratories Ltd.
  • Raybiotech, Inc.
  • Svar Life Science AB

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29593

Global Biomarker Testing Services Market to Reach US$1.1 Billion by 2030

The global market for Biomarker Testing Services estimated at US$700.5 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Biomarker Assay Development & Validation Service, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$762.6 Million by the end of the analysis period. Growth in the Flow Cytometry Service segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$184.1 Million While China is Forecast to Grow at 7.9% CAGR

The Biomarker Testing Services market in the U.S. is estimated at US$184.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$178.7 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Biomarker Testing Services Market - Key Trends & Drivers Summarized

Why Is Biomarker Testing Gaining Importance in Modern Healthcare?

Biomarker testing has become a cornerstone of precision medicine, enabling early disease detection, treatment monitoring, and patient stratification for targeted therapies. With the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions, the need for reliable biomarker testing services has surged. These services facilitate more accurate diagnosis and treatment selection, ensuring better patient outcomes and reduced healthcare costs. The increasing reliance on biomarker-based diagnostics is also evident in the rapid expansion of personalized medicine. Pharmaceutical companies are integrating biomarker testing into drug development processes to identify patient populations that would benefit most from specific therapies. Additionally, regulatory agencies are mandating biomarker testing for companion diagnostics, ensuring drug efficacy and safety before market approval. As a result, healthcare providers and diagnostic laboratories are increasingly outsourcing biomarker testing services to specialized laboratories with advanced analytical capabilities.

How Are Technological Innovations Enhancing Biomarker Testing Services?

Technological advancements in genomics, proteomics, and bioinformatics are revolutionizing biomarker testing services, making them more precise, cost-effective, and accessible. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have improved the detection of genetic and molecular biomarkers, allowing for earlier disease identification and risk assessment. Additionally, the integration of artificial intelligence (AI) and machine learning in biomarker data analysis is optimizing test accuracy and accelerating result interpretation. The emergence of liquid biopsy techniques is another groundbreaking development in biomarker testing. These minimally invasive tests enable real-time monitoring of disease progression by analyzing circulating tumor DNA (ctDNA) and other biomarkers in blood samples. Furthermore, advancements in multiplex biomarker assays allow for simultaneous testing of multiple biomarkers, reducing time and costs associated with traditional single-marker tests. As healthcare moves toward data-driven decision-making, these innovations are making biomarker testing services an indispensable tool in modern diagnostics and drug development.

What Market Trends Are Driving the Growth of Biomarker Testing Services?

The growing demand for early disease detection and personalized treatment plans is one of the key trends propelling the biomarker testing services market. Healthcare providers and researchers are prioritizing precision diagnostics to tailor treatments to individual patient profiles, leading to increased adoption of biomarker testing across various medical specialties. Oncology remains the largest application area, with biomarker-driven therapies playing a crucial role in immunotherapy, targeted cancer treatments, and chemotherapy response assessment. Another significant trend shaping the market is the rise of decentralized testing models. The shift toward home-based and point-of-care biomarker testing is being fueled by advances in telemedicine and remote patient monitoring technologies. Companies are developing portable biomarker testing kits and wearable biosensors to facilitate real-time health tracking, reducing the need for frequent hospital visits. Moreover, regulatory support for biomarker-driven clinical trials and drug approvals is encouraging pharmaceutical firms to integrate biomarker testing into their development pipelines, further boosting market demand.

What Are the Key Growth Drivers for the Biomarker Testing Services Market?

The growth in the Biomarker Testing Services market is driven by several factors including the rising incidence of chronic diseases, increasing adoption of precision medicine, and rapid technological advancements in biomarker detection methods. The expansion of companion diagnostics, which require biomarker testing for drug approval and patient selection, is further fueling market growth. Additionally, the increasing investment in clinical research and biotechnology innovations is expanding the scope of biomarker testing applications. Pharmaceutical companies are leveraging biomarker testing services to streamline drug development, reduce clinical trial failures, and enhance regulatory compliance. The shift toward non-invasive diagnostic techniques, such as liquid biopsy and multiplex biomarker panels, is also accelerating market expansion. As healthcare systems worldwide focus on improving diagnostic accuracy and treatment efficacy, biomarker testing services are expected to experience sustained growth, transforming the future of disease management and precision medicine.

SCOPE OF STUDY:

The report analyzes the Biomarker Testing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service (Biomarker Assay Development & Validation Service, Flow Cytometry Service, Other Services); Type (Molecular Biomarkers, Cellular Biomarkers); End-Use (Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use, CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 22 Featured) -

  • ACM Global Laboratories
  • BioAgilytix Labs, LLC
  • Biomedica Medizinprodukte GmbH
  • Charles River Laboratories, Inc.
  • Creative Biolabs
  • Discovery Life Sciences
  • Frontage Laboratories, Inc.
  • Intertek Group Plc
  • Laboratory Corporation of America Holdings
  • NorthEast BioLab
  • Novigenix SA
  • Pacific Biolabs
  • Randox Laboratories Ltd.
  • Raybiotech, Inc.
  • Svar Life Science AB

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biomarker Testing Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expansion of Precision Medicine and Targeted Therapies Throws the Spotlight on Biomarker Testing Services
    • Rising Clinical Demand for Companion Diagnostics Drives Hospital and Lab Adoption of Biomarker Assays
    • Surge in Liquid Biopsy-Based Testing Accelerates Use of Non-Invasive Biomarkers in Clinical Decision-Making
    • OEM Focus on Multi-Gene Panels and Comprehensive Genomic Profiling Spurs Testing Service Innovation
    • Increased Use of Immune Checkpoint and MSI Markers in Oncology Fuels Growth of Specialized Testing Panels
    • Regulatory Approvals for Lab-Developed Tests and IVD Companion Diagnostics Support Market Commercialization
    • Growing Integration of Molecular Pathology and Centralized Lab Services Enhances Biomarker Testing Capacity
    • Expansion of Testing in Neurology, Cardiology, and Infectious Diseases Broadens Clinical Application Landscape
    • Use of AI for Pathology Image-Based Biomarker Detection Strengthens Digital Testing Platforms
    • Rising Demand for Real-Time Monitoring Biomarkers in Chronic Disease Management Propels Market Uptake
    • Growth in Hospital-Acquired Infection Biomarker Testing Supports Rapid Triage and Antibiotic Stewardship
    • OEM Partnerships With Diagnostic Labs Enhance Sample Volume and Data Generation for Longitudinal Studies
    • Development of Point-of-Care and Decentralized Testing Devices Fuels Access to Biomarker Testing in Rural Areas
    • OEM Investment in Harmonized Sample-to-Insight Workflows Improves Testing Efficiency and Clinical Turnaround
    • Expansion of Next-Generation Sequencing and PCR Infrastructure Supports Multiplexed Biomarker Analysis
    • Integration With EHR Systems and AI-Based Reporting Engines Enhances Clinical Decision Support Capabilities
    • Global Rollout of Tumor-Agnostic Therapies Strengthens Role of Genotype-Based Biomarker Testing
    • Demand for Cost-Effective Panel-Based Tests Encourages Adoption in Community Hospitals and Labs
    • Focus on Test Reproducibility and CLIA/CAP Compliance Drives Quality Assurance in Biomarker Testing Services
    • Shift Toward Value-Based Healthcare Models Supports Reimbursement for Outcome-Linked Biomarker Tests
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Biomarker Assay Development & Validation Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Biomarker Assay Development & Validation Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Flow Cytometry Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Flow Cytometry Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Molecular Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Molecular Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Cellular Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Cellular Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Biomarker Testing Services Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Biomarker Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Biomarker Testing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • JAPAN
    • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • CHINA
    • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • EUROPE
    • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Biomarker Testing Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • GERMANY
    • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • UNITED KINGDOM
    • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030

IV. COMPETITION